CDEK
← All organizations
SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics, Inc.

For profitContributed to NMEWebsite ↗

Also known as: SPRINGWORKS | SpringWorks Therapeutics, Inc.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Mar 28, 2019

First marketed drug

Nov 27, 2023

First NDA

Nov 27, 2023

Last known activity

Dec 31, 2025

Acquired by Merck Serono on Apr 28, 2025

Timeline

2010s

  1. Jun 1, 2017

    SpringWorks Therapeutics, Inc.— Founded

2020s

  1. Nov 27, 2023

    nirogacestat— Marketing Organization

  2. Nov 27, 2023

    nirogacestat— NDA Organization

  3. Apr 28, 2025

    Merck Serono— Acquired By

Drugs by trial phase (9 distinct, 19 trials)

Phase 4 (1 own, 0 via acquisition)

Phase 2 (4 own, 0 via acquisition)

Phase 1 (4 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (2)

Recent trials (19)

Details

Founded
Stamford, CT, US Jun 1, 2017
First NDA
Nov 27, 2023
Last known activity
Dec 31, 2025

Designations held

  • Orphan drug
  • Fast track
  • Priority review
  • Breakthrough therapy